Literature DB >> 34212828

Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors.

Ligong Liu1, Lilong Dong2, Erika Bourguet3, David P Fairlie1.   

Abstract

This review summarizes key literature defining the phenotypes of individual class IIa HDAC proteins and compounds that selectively target their enzymatic catalytic domain (CD). The focus is on the effects of class IIa HDACs in physiological and pathological conditions, both in vitro and in vivo, and on their mode of action in regulating genes, upstream proteins and signaling pathways. Phenotype studies further demonstrate either beneficial or detrimental effects of silencing selected class IIa HDACs or their enzymatic properties. We also summarize the knowledge gained from structure-activity relationships of CD inhibitors as well as molecular mechanisms underpinning isozyme selectivity where crystal structures or modelling studies are available. Given that the number of genes affected by silencing class IIa HDACs is much smaller than class I, the role of gene regulation of class IIa HDACs could be much more selective. Since class IIa HDACs have restricted tissue distributions and multiple functions independent of their CD, targeting the CD of class IIa HDACs could lead to more selective therapeutic agents with significantly fewer side-effects than other HDAC ligands. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Drug discovery; HDAC isoforms; catalytic domain inhibitor.; class IIa HDAC; epigenetic regulation; histone deacetylase; inhibitor; phenotype

Mesh:

Substances:

Year:  2021        PMID: 34212828     DOI: 10.2174/0929867328666210629160647

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  1 in total

1.  Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods.

Authors:  Rourou Li; Yujia Tian; Zhenwu Yang; Yueshan Ji; Jiaqi Ding; Aixia Yan
Journal:  Mol Divers       Date:  2022-06-23       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.